Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel T Wilkinson

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Journal of Affective Disorders|August 11, 2019
Longer-term open-label study of adjunctive riluzole in treatment-resistant depressionHitoshi Sakurai, Christina Dording, Albert Yeung, et al.
The International Journal of Neuropsychopharmacology|May 4, 2025
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension studyNaim Zaki, Li Nancy Chen, Rosanne Lane, et al.
The Journal of Clinical Psychiatry|September 3, 2025
Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D TrialKristina T Kumpf, Samuel T Wilkinson, Bo Hu, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|November 18, 2019
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3Rachel Ochs-Ross, Ella J Daly, Yun Zhang, et al.
Contemporary Clinical Trials|December 21, 2018
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocolSanjay J Mathew, Samuel T Wilkinson, Murat Altinay, et al.
JAMA Network Open|August 8, 2025
A Digital Therapeutic Intervention for Inpatients With Elevated Suicide Risk: A Randomized Clinical TrialCraig J Bryan, Patricia Simon, Samuel T Wilkinson, et al.
Molecular Psychiatry|October 5, 2018
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)Maurizio Fava, Marlene P Freeman, Martina Flynn, et al.
Molecular Psychiatry|January 9, 2019
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)Maurizio Fava, Marlene P Freeman, Martina Flynn, et al.
Journal of Cardiac Failure|June 24, 2021
The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT TrialFouad Chouairi, Michael A Fuery, Clancy W Mullan, et al.
JAMA Network Open|June 25, 2024
Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical TrialManish Kumar Jha, Samuel T Wilkinson, Kamini Krishnan, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Journal of Affective Disorders|August 11, 2019
Longer-term open-label study of adjunctive riluzole in treatment-resistant depressionHitoshi Sakurai, Christina Dording, Albert Yeung, et al.
The International Journal of Neuropsychopharmacology|May 4, 2025
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension studyNaim Zaki, Li Nancy Chen, Rosanne Lane, et al.
The Journal of Clinical Psychiatry|September 3, 2025
Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D TrialKristina T Kumpf, Samuel T Wilkinson, Bo Hu, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|November 18, 2019
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3Rachel Ochs-Ross, Ella J Daly, Yun Zhang, et al.
Contemporary Clinical Trials|December 21, 2018
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocolSanjay J Mathew, Samuel T Wilkinson, Murat Altinay, et al.
JAMA Network Open|August 8, 2025
A Digital Therapeutic Intervention for Inpatients With Elevated Suicide Risk: A Randomized Clinical TrialCraig J Bryan, Patricia Simon, Samuel T Wilkinson, et al.
Molecular Psychiatry|October 5, 2018
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)Maurizio Fava, Marlene P Freeman, Martina Flynn, et al.
Molecular Psychiatry|January 9, 2019
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)Maurizio Fava, Marlene P Freeman, Martina Flynn, et al.
Journal of Cardiac Failure|June 24, 2021
The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT TrialFouad Chouairi, Michael A Fuery, Clancy W Mullan, et al.
JAMA Network Open|June 25, 2024
Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical TrialManish Kumar Jha, Samuel T Wilkinson, Kamini Krishnan, et al.
Pageof 11